News - Astellas Pharma, Licensing


Current filters:

Astellas PharmaLicensing

Popular Filters

Cumberland Pharma acquires Vaprisol from Astellas


USA-based Cumberland Pharmaceuticals says it has acquired from the US subsidiary of Japan’s Astellas…

Astellas PharmaCumberland PharmaceuticalsHematologyLicensingNorth AmericaPharmaceuticalUSAVaprisol

Astellas amends license deal for isavuconazole with Basilea


Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

AVEO and Astellas finally terminate tivozanib collaboration


US biotech firm AVEO Oncology and Japanese drug major Astellas Pharma are to end their worldwide collaboration…

Astellas PharmaAVEO OncologyBiotechnologyLicensingOncologytivozanib

Astellas links with Mitokyne on mitochondria-related therapies

Astellas links with Mitokyne on mitochondria-related therapies


Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D…

Astellas PharmaFinancialLicensingMergers & AcquisitionsMitokynePharmaceuticalResearch

Merck & Co to co-promote diabetes agent ipragliflozin in Japan


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

AstraZeneca to fork out $815 million for rights to anemia drug candidate


In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Seattle Genetics takes up option to co-develop additional ADC with Astellas


Japanese drug major Astellas Pharma (TYO: 4503) says that US biotech firm Seattle Genetics (Nasdaq: SGEN)…

ASG-15MEAstellas PharmaBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

Astellas and Cytokinetics collaborate on new frontier of muscle biology


In a second deal announced this month by US biotech firm, Cytokinetics (Nasdaq: CYTK) has entered into…

Astellas PharmaBiotechnologyCK-2127107CytokineticsLicensingPharmaceuticalResearch

Drais Pharma to develop third Astellas compound through Tacurion


Japanese drug major Astellas Pharma (TYO: 4503) and USA-based Drais Pharmaceuticals have entered into…

ASP7035Astellas PharmaDrais PharmaceutialsGenito-urinaryLicensingPharmaceuticalResearchTacurion

Astellas and Ambrx collaborate in up to $300 oncology deal; Teijin takes stake in Kyorin


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with venture capital…

AmbrxAstellas PharmaKyorin PharmaceuticalsLicensingMergers & AcquisitionsOncologyPharmaceuticalTeijin

Astellas ends FLT3 deal with Ambit; reports on flu vaccine ASP7374


The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) and USA-based privately held firm…

Ambit BiosciencesASP7374Astellas PharmaLicensingOncologyPharmaceuticalquizartinibResearchVaccines

Clinigen and Theravance deal on Vibativ; Cubist expands rights to ceftolozane


UK-based Clinigen Group (LSE: CLIN ) and Theravance (Nasdaq: THRX) of the USA have entered into an exclusive…

Antibiotics and Infectious diseasesAstellas PharmaceftolozaneClinigen GroupCubist PharmaceuticalsEuropeGlobalLicensingPharmaceuticalTheravanceVibativ

Merck & Co in Nanobody deal with Ablynx; J&J and Astellas join forces on RA


US pharma giant Merck & Co (NYSE: MRK) has entered into a collaboration with Belgium's Ablynx (Euronext…

AblynxAnti-Arthritics/RheumaticsASPO15KAstellas PharmaBiotechnologyJohnson & JohnsonLicensingMerck & CoPharmaceutical

Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe


USA-Based Optimer Pharmaceuticals (Nasdaq: OPTR) says that it is set to receive 10 million euros ($12.5…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropeFinancialLicensingOptimer PharmaceuticalsPharmaceutical

Astellas partners with Drais to develop its ulcerative colitis compound


apanese drug major Astellas Pharma (TYO: 4503) has entered into a uniquely structured partnership with…

Astellas PharmaDrais PharmaceutialsGastro-intestinalsLicensingPharmaceuticalTelsar Pharma

Optimer Pharma could earn $90 million from new Astellas deal


US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

UCB links with Astellas for Cimzia in Japan


Following the recent discontinuation of a commercialization accord for its rheumatoid arthritis drug…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCimziaLicensingPharmaceuticalUCB

Astellas pulls out of deal with Theravance


Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

Astellas in-licenses antibody from Evec; Mitsubishi Tanabe deal with Synageva


Japanese biotech firm Evec has entered a license agreement for one of its fully-human antibodies against…

Asia-PacificAstellas PharmaBiotechnologyEvecImmunologicalsLicensingMitsubishi TanabePharmaceuticalRare diseasesResearchSynageva BioPharma

Teijin and Astellas expand collaboration on gout drug febuxostat


Japanese drugmakers Teijin Pharma (TYO: 3401 and Astellas Pharma (TKO:4503) have entered into an exclusive…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmafebuxostatLicensingPharmaceuticalTeijin

Merck & Co gets North American and Mexican rights to vernakalant iv from Astellas


US drug giant Merck & Co (NYSE: MRK) has entered into an agreement with Japan’s Astellas Pharma…

Astellas PharmaCardio-vascularCardiome PharmaLicensingMerck & CoNorth AmericaPharmaceuticalvernakalant

Back to top